The cobas® SARS-CoV-2 Test provides reliable and high-quality results for clinical decision-making for the improved management of COVID-19 patients and to reduce the risk of SARS-CoV-2 (coronavirus) infection. Healthcare professionals use these tests to assess if patients are at risk of developing disease by this pathogen, which can contribute to severe upper respiratory distress, complications, and potential death.
The Gencurix GenePro COVID-19 Detection Test is a RT-PCR kit for the detection of SARS-CoV-2 developed based on WHO interim guidelines. The test qualitatively detects the RdRP and E genes simultaneously.
The Nanjing Vazyme 2019-nCoV IgG/IgM Detection Kit is intended to detect the IgG / IgM of 2019-Novel Coronavirus (2019-nCoV) from human serum, plasma and whole blood. This product produces rapid results and does not require any additional laboratory equipment.
AccuPower®COVID-19 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 infections, detects SARS-CoV-2 (E gene and RdRp gene) RNA from a suspected infection patient’s sample (such as sputum, nasopharyngeal swab, oropharyngeal swab) through Real-Time Polymerase chain reaction(PCR) using ExiStation™ Universal MDx system.
VereCoV™ Detection Kit is a multiplex RT-PCR and microarray-based test. This test is for use in conjunction with the VerePLEX™ Biosystem. The test is intended for qualitative detection, differentiation and identification of the 2019 Novel Coronavirus (2019-nCoV) and Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV).
The CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel is a molecular in vitro diagnostic test that aids in the detection and diagnosis 2019-nCoV and is based on widely used nucleic acid amplification technology. The product contains oligonucleotide primers and dual-labeled hydrolysis probes (TaqMan®) and control material used in rRT-PCR for the in vitro qualitative detection of 2019-nCoV RNA in respiratory specimens.
The A*STAR FORTITUDE KIT 2.0 is based on real-time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) technology, for the qualitative detection of SARS-CoV-2 specific RNA in nasopharyngeal swab samples. A positive result from the test indicates the presence of SARS-CoV-2 specific RNA in the test sample.
The first FDA-approved COVID-19 rapid test kit. The Cellex qSARS-CoV-2 IgG/IgM Rapid Test is a lateral flow immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in serum, plasma (EDTA, citrate) or venipuncture whole blood specimens from patients suspected of COVID-19 infection.